21. The coating of claim 20 wherein the dry powder medicament is ethinyl estradiol.

22. The coating of claim 1 further comprising norgestimate.

23. The coating of claim 21 wherein the ethinyl estradiol is present in an amount in the range of from about 20 μg to about 50 μg.

24. The coating of claim 21 wherein the ethinyl estradiol is present in an amount in the range of from about 30 μg to about 40 μg.

25. The coating of claim 21 wherein the ethinyl estradiol is present in an amount of about 35 μg.

26. The coating of claim 21 wherein the ethinyl estradiol is micronized to a particle size in the range of from about 5 μm to about 20 μm.

A1 cont.

27. The coating of claim 21 wherein the ethinyl estradiol is micronized to a particle size in the range of from about 5 μm to about 10 μm.

28. The coating of claim 22 wherein the norgestimate is present in an amount in the range of from about 30 μg to about 250 μg.

29. The coating of claim 22 wherein the norgestimate is micronized to a particle size in the range of from about 5 μm to about 20 μm.

30. The coating of claim 22 wherein the norgestimate is micronized to a particle size in the range of from about 5 μm to about 15 μm.

31. The coating of claim 20 wherein the polyethylene glycol is micronized to a particle size in the range of from about 5 μm to about 10 μm.

32. The coating of claim 20 wherein the polyethylene glycol has a molecular weight in the range of from about 6000 to about 8000.

33. The coating of claim 20 wherein the polyethylene glycol has a molecular weight of about 8000.

34. The coating of claim 20 wherein the polyethylene glycol has a molecular weight of about 6000.

35. The coating of claim 20 wherein the ratio of dry powder medicament to polyethylene glycol is from about 1:1 to about 1:60.

36. The coating of claim 20 wherein the ratio of dry powder medicament to polyethylene glycol is from about 1:1 to about 1:40. --